Evidence map›Paper›PMID 32196495›Full record

ArticlePLoS computational biology2020

Computational design of substrate selective inhibition.

Benny Da'adoosh, Kon Kaito, Keishi Miyashita, Minoru Sakaguchi, Amiram Goldblum

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Frontiers in cell and developmental biology · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Benny Da'adooshMolecular Modeling Laboratory, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel.
Kon KaitoLaboratory of Cell Biology, Osaka University of Pharmaceutical Sciences, Osaka, Japan.ORCID 0000-0002-3011-5445
Keishi MiyashitaLaboratory of Cell Biology, Osaka University of Pharmaceutical Sciences, Osaka, Japan.ORCID 0000-0003-3209-2272
Minoru SakaguchiLaboratory of Cell Biology, Osaka University of Pharmaceutical Sciences, Osaka, Japan.
Amiram GoldblumMolecular Modeling Laboratory, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel.
Osaka University of Pharmaceutical Sciences · JPHebrew University of Jerusalem · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most enzymes act on more than a single substrate. There is frequently a need to block the production of a single pathogenic outcome of enzymatic activity on a substrate but to avoid blocking others of its catalytic actions. Full blocking might cause severe side effects because some products of that catalysis may be vital. Substrate selectivity is required but not possible to achieve by blocking the catalytic residues of an enzyme. That is the basis of the need for "Substrate Selective Inhibitors" (SSI), and there are several molecules characterized as SSI. However, none have yet been designed or discovered by computational methods. We demonstrate a computational approach to the discovery of Substrate Selective Inhibitors for one enzyme, Prolyl Oligopeptidase (POP) (E.C 3.4.21.26), a serine protease which cleaves small peptides between Pro and other amino acids. Among those are Thyrotropin Releasing Hormone (TRH) and Angiotensin-III (Ang-III), differing in both their binding (Km) and in turnover (kcat). We used our in-house "Iterative Stochastic Elimination" (ISE) algorithm and the structure-based "Pharmacophore" approach to construct two models for identifying SSI of POP. A dataset of ~1.8 million commercially available molecules was initially reduced to less than 12,000 which were screened by these models to a final set of 20 molecules which were sent for experimental validation (five random molecules were tested for comparison). Two molecules out of these 20, one with a high score in the ISE model, the other successful in the pharmacophore model, were confirmed by in vitro measurements. One is a competitive inhibitor of Ang-III (increases its Km), but non-competitive towards TRH (decreases its Vmax).

Indexed as

Enzyme InhibitorsSubstrate SpecificityAlgorithmsComputational BiologyComputer SimulationDrug DiscoveryHumansProlyl OligopeptidasesSerine EndopeptidasesEnzyme InhibitorsPREPL protein, humanProlyl OligopeptidasesSerine Endopeptidases

Identifiers

PMID32196495
PMCPMC7112232
OpenAlexW3011185263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.